Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEILIVCA Study
2008-002269-29Phase 3Terminated
- Sponsor
- Heidelberg University Hospital
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing TACE + sorafenib with TACE + placebo (2 arms). Primary endpoint: Time to progression. Started Jan 2009; status: terminated.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2008-002269-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002269-29.